

# MANTLE CELL LYMPHOMA:

NOW and BEYOND

ROME June 27, 2022 Donna Camilla Savelli Hotel

## Mantle Cell lymphoma: Update on pathobiology



Stefano A. Pileri



MANTLE CELL LYMPHOMA: NOW and BEYOND

ROME June 27, 2022

## Disclosures of Stefano Pileri

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
BeiGene						X	
Roche					X		
Takeda						X	
Diatech						X	
Morphosys			X				

MANTLE CELL LYMPHOMA: **NOW and BEYOND**

ROME June 27, 2022

MANTLE CELL LYMPHOMA: **NOW and BEYOND**

ROME June 27, 2022



WHO



OMS

International Agency for Research on Cancer (IARC)

Revised 4th Edition

# **WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues**

Edited by

Steven H. Swerdlow

Elias Campo


Nancy Lee Harris

Elaine S. Jaffe



Stefano A. Pileri

Harald Stein


Jürgen Thiele











# MCL Growth Patterns



Epithelioid  
histiocytes









# KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

<b>Patients Characteristics</b>		<b>N = 68</b>
<b>Median no. of prior therapies (range)*</b>		3 (1-5)
≥ 3 prior lines of therapy, n (%)		55 (81)
<b>Anthracycline or bendamustine, n (%)</b>		67 (99)
Anthracycline		49 (72)
Bendamustine		37 (54)
<b>BTKi, n (%)</b>		68 (100)
Ibrutinib		58 (85)
Acalabrutinib		16 (24)
Both		6 (9)
<b>Relapsed/refractory subgroup, n (%)</b>		
Relapsed after autologous SCT		29 (43)
Refractory to last prior therapy		27 (40)
Relapsed after last prior therapy		12 (18)
<b>BTKi relapsed/refractory status, n (%)</b>		68 (100)
Refractory to BTKi		42 (62)
Relapsed on BTKi		18 (26)
Relapsed after BTKi		5 (7)
Intolerant to BTKi†		3 (4)

**brexucabtagene autoleucel (KTE-X19, brexu-cel)** was successfully manufactured for 71 patients (96%) and administered to 68 patients (92%)


- Median time from leukapheresis to delivery of KTE-X19 to the study site was 16 days




The **NEW ENGLAND**  
**JOURNAL** of **MEDICINE**




**CD20**



**CD5**






**CD23**





# Aberrant expression of CD10 and BCL6 in mantle cell lymphoma

Marco Pizzi,<sup>1</sup> Claudio Agostinelli,<sup>2</sup>  Simona Righi,<sup>2</sup> Anna Gazzola,<sup>2</sup> Claudia Mannu,<sup>2</sup> Francesca Galuppini,<sup>1</sup> Matteo Fassan,<sup>1</sup>  Andrea Visentin,<sup>3</sup> Francesco Piazza,<sup>3</sup> Gianpietro C Semenzato,<sup>3</sup> Massimo Rugge<sup>1</sup> & Elena Sabattini<sup>2</sup> 

---

## CD5-negative Mantle Cell Lymphoma

### *Clinicopathologic Correlations and Outcome in 58 Patients*

*Yuan Miao, MD, PhD,\*† Pei Lin, MD,\* Annapurna Saksena, MD,\* Jie Xu, MD, PhD,\*  
Michael Wang, MD,‡ Jorge Romaguera, MD,‡ C. Cameron Yin, MD, PhD,\*  
L. Jeffrey Medeiros, MD,\* and Shaoying Li, MD\** (*Am J Surg Pathol* 2019;00:000–000)

---

## CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis ☆,☆☆

Annapurna Saksena MD<sup>a,b</sup>, C. Cameron Yin MD, PhD<sup>a</sup>, Jie Xu MD, PhD<sup>a</sup>, Jingyi Li MD<sup>a,c</sup>, Jiehao Zhou MD, PhD<sup>d</sup>, Sa A. Wang MD<sup>a</sup>, Pei Lin MD<sup>a</sup>, Guilin Tang MD, PhD<sup>a</sup>, Lifu Wang MD<sup>a,e</sup>, Michael Wang MD<sup>f</sup>, Roberto N. Miranda MD<sup>a</sup>, L. Jeffrey Medeiros MD<sup>a</sup>, Shaoying Li MD<sup>a,\*</sup>



## LYMPHOID NEOPLASIA

# *CCND2* and *CCND3* hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphoma











David Martín-García,<sup>1,2,\*</sup> Alba Navarro,<sup>1,2,\*</sup> Rafael Valdés-Mas,<sup>3</sup> Guillem Clot,<sup>1,2</sup> Jesús Gutiérrez-Abril,<sup>3</sup> Miriam Prieto,<sup>1,2</sup> Inmaculada Ribera-Cortada,<sup>4</sup> Renata Woroniecka,<sup>5</sup> Grzegorz Rymkiewicz,<sup>6</sup> Susanne Bens,<sup>7,8</sup> Laurence de Leval,<sup>9</sup> Andreas Rosenwald,<sup>10,11</sup> Judith A. Ferry,<sup>12</sup> Eric D. Hsi,<sup>13</sup> Kai Fu,<sup>14,15</sup> Jan Delabie,<sup>16,17</sup> Dennis Weisenburger,<sup>18</sup> Daphne de Jong,<sup>19</sup> Fina Climent,<sup>20</sup> Sheila J. O'Connor,<sup>21</sup> Steven H. Swerdlow,<sup>22</sup> David Torrents,<sup>23,24</sup> Sergi Beltran,<sup>25</sup> Blanca Espinet,<sup>26,27</sup> Blanca González-Farré,<sup>2,28</sup> Luis Veloza,<sup>28</sup> Dolors Costa,<sup>2,28</sup> Estella Matutes,<sup>28</sup> Reiner Siebert,<sup>7,8</sup> German Ott,<sup>29,30</sup> Leticia Quintanilla-Martinez,<sup>31</sup> Elaine S. Jaffe,<sup>32</sup> Carlos López-Otín,<sup>2,3</sup> Itziar Salaverria,<sup>1,2</sup> Xose S. Puente,<sup>2,3,†</sup> Elias Campo,<sup>1,2,28,33,†</sup> and Sílvia Beà<sup>1,2,†</sup>

**(Blood. 2019;133(9):940-951)**




## LYMPHOMA

# Insights into the mechanisms underlying aberrant *SOX11* oncogene expression in mantle cell lymphoma

Roser Vilarrasa-Blasi <sup>1,2</sup>✉, Núria Verdaguer-Dot<sup>1</sup>, Laura Berver<sup>3,4</sup>, Paula Soler-Vila<sup>5</sup>, Renée Beekman<sup>1</sup>, Vicente Chapaprieta <sup>1</sup>, Marta Kulis<sup>1</sup>, Ana C. Queirós<sup>1</sup>, Maribel Parra <sup>4</sup>, María José Calasanz <sup>6,7</sup>, Xabier Agirre <sup>6,7</sup>, Felipe Prosper <sup>6,7,8</sup>, Sílvia Beà<sup>1,2,7</sup>, Dolors Colomer <sup>1,2,7</sup>, Marc A. Marti-Renom<sup>5,9</sup>, Adolfo Ferrando <sup>3</sup>, Elías Campo <sup>1,2,7</sup> and José Ignacio Martin-Subero <sup>1,2,7,9</sup>✉


© The Author(s), under exclusive licence to Springer Nature Limited 2021

*Leukemia* (2022) 36:583–587; <https://doi.org/10.1038/s41375-021-01389-w>





### Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network



*Eva Hoster, Andreas Rosenwald, Françoise Berger, Heinz-Wolfram Bernd, Sylvia Hartmann, Christoph Loddenkemper, Thomas F.E. Barth, Nicole Brousse, Stefano Pileri, Grzegorz Rymkiewicz, Roman Kodet, Stephan Stilgenbauer, Roswitha Forstpointner, Catherine Thieblemont, Michael Hallek, Bertrand Coiffier, Ursula Vehling-Kaiser, Réda Bouabdallah, Lothar Kanz, Michael Pfreundschuh, Christian Schmidt, Vincent Ribrag, Wolfgang Hiddemann, Michael Unterhalt, Johanna C. Kluijn-Nelemans, Olivier Hermine, Martin H. Dreyling, and Wolfram Klapper*




**Ki-67 index**



# Variable Expression of Proliferation Signature Genes in Mantle Cell Lymphoma



**Rosenwald A et LLMP, Cancer Cell 2003;  
3(2):185-97.**





*Virchows Arch.* 2020 August ; 477(2): 259–267. doi:10.1007/s00428-020-02750-7.

## **Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11**

**Giorgio A. Croci<sup>1,2</sup>, Eva Hoster<sup>3,4</sup>, Sílvia Bea<sup>5,6</sup>, Guillem Clot<sup>5,6</sup>, Anna Enjuanes<sup>5,6</sup>, David W. Scott<sup>7</sup>, José Cabeçadas<sup>8</sup>, Luis Veloza<sup>9</sup>, Elias Campo<sup>5,6,9</sup>, Erik Clasen-Linde<sup>10</sup>, Rashmi S. Goswami<sup>11</sup>, Lars Helgeland<sup>12</sup>, Stefano Pileri<sup>13</sup>, Grzegorz Rymkiewicz<sup>14</sup>, Sarah Reinke<sup>1</sup>, Martin Dreyling<sup>4</sup>, Wolfram Klapper<sup>1</sup>**

<b>MCL*</b>	
<b>Conventional</b>	<b>Leukemic nonnodal</b>
Naive B-cell-like	Memory B-cell-like
Unexperienced†	Experienced†
Naive-like	Memory-like
98.7 ( $\pm$ 2.6)†	95.1 ( $\pm$ 1.5)†
IGHV4-34	IGHV4-34
IGHV5-51	IGHV5-51
IGHV3-21	IGHV1-8
IGHV3-23	IGHV4-59
<i>ATM, CDKN2A del</i>	<i>CCND1, TLR2</i>

## LYMPHOID NEOPLASIA

# Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Prasath Pararajalingam,<sup>1,\*</sup> Krysta M. Coyle,<sup>1,\*</sup> Sarah E. Arthur,<sup>1</sup> Nicole Thomas,<sup>1</sup> Miguel Alcaide,<sup>1</sup> Barbara Meissner,<sup>2,3</sup> Merrill Boyle,<sup>2,3</sup> Quratulain Qureshi,<sup>1</sup> Bruno M. Grande,<sup>1</sup> Christopher Rushton,<sup>1</sup> Graham W. Slack,<sup>2,3</sup> Andrew J. Mungall,<sup>4</sup> Constantine S. Tam,<sup>5,6</sup> Rishu Agarwal,<sup>5</sup> Sarah-Jane Dawson,<sup>5,6</sup> Georg Lenz,<sup>7</sup> Sriram Balasubramanian,<sup>8</sup> Randy D. Gascoyne,<sup>2,3</sup> Christian Steidl,<sup>2,3</sup> Joseph Connors,<sup>2,3</sup> Diego Villa,<sup>2,3</sup> Timothy E. Audas,<sup>1</sup> Marco A. Marra,<sup>2,3</sup> Nathalie A. Johnson,<sup>9</sup> David W. Scott,<sup>2,3</sup> and Ryan D. Morin<sup>1,4</sup>


<sup>1</sup>Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; <sup>2</sup>BC Cancer Centre for Lymphoid Cancer and <sup>3</sup>BC Cancer Research Centre, Vancouver, BC, Canada; <sup>4</sup>Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; <sup>5</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; <sup>6</sup>University of Melbourne, Melbourne, VIC, Australia; <sup>7</sup>Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany; <sup>8</sup>Janssen Research and Development, San Diego, CA; and <sup>9</sup>Department of Medicine, Jewish General Hospital, Montreal, QC, Canada

### KEY POINTS

- RNA-binding proteins with roles in regulating alternative splicing, *DAZAP1*, *EWSR1*, *HNRNPH1*, are frequently mutated in MCL.
- Most somatic *HNRNPH1* mutations are intronic and disrupt regulation of *HNRNPH1* through alternative splicing.

**Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standard therapies. The genetic drivers of this cancer have not been firmly established, and the features that contribute to differences in clinical course remain limited. To extend our understanding of the biological pathways involved in this malignancy, we performed a large-scale genomic analysis of MCL using data from 51 exomes and 34 genomes alongside previously published exome cohorts. To confirm our findings, we resequenced the genes identified in the exome cohort in 191 MCL tumors, each having clinical follow-up data. We confirmed the prognostic association of *TP53* and *NOTCH1* mutations. Our sequencing revealed novel recurrent noncoding mutations surrounding a single exon of the *HNRNPH1* gene. In RNA-seq data from 103 of these cases, MCL tumors with these mutations had a distinct imbalance of *HNRNPH1* isoforms. This altered splicing of *HNRNPH1* was associated with inferior outcomes in MCL and showed a significant increase in protein expression by immunohistochemistry. We describe a functional role for these recurrent noncoding mutations in disrupting an autoregulatory feedback mechanism,**

**thereby deregulating *HNRNPH1* protein expression. Taken together, these data strongly imply a role for aberrant regulation of messenger RNA processing in MCL pathobiology. (*Blood*. 2020;136(5):572-584)**





# Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Rahul Lakhota,<sup>1</sup> Christopher Melani,<sup>1</sup> Kieron Dunleavy,<sup>2</sup> Stefania Pittaluga,<sup>3</sup> Nakhle Saba,<sup>4</sup> Liza Lindenberg,<sup>5</sup> Esther Mena,<sup>5</sup> Ethan Bergvall,<sup>6</sup> Andrea Nicole Lucas,<sup>7</sup> Allison Jacob,<sup>8</sup> Erik Yusko,<sup>8</sup> Seth M. Steinberg,<sup>9</sup> Elaine S. Jaffe,<sup>3</sup> Adrian Wiestner,<sup>10</sup> Wyndham H. Wilson,<sup>1,\*</sup> and Mark Roschewski<sup>1,\*</sup>

26 APRIL 2022 • VOLUME 6, NUMBER 8

2667




# Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song,<sup>1</sup> Keshu Zhou,<sup>2</sup> Dehui Zou,<sup>3</sup> Jianfeng Zhou,<sup>4</sup> Jianda Hu,<sup>5</sup> Haiyan Yang,<sup>6</sup> Huilai Zhang,<sup>7</sup> Jie Ji,<sup>8</sup> Wei Xu,<sup>9</sup> Jie Jin,<sup>10</sup> Fangfang Lv,<sup>11</sup> Ru Feng,<sup>12</sup> Sujun Gao,<sup>13</sup> Haiyi Guo,<sup>14</sup> Lei Zhou,<sup>15</sup> Jane Huang,<sup>16</sup> William Novotny,<sup>16</sup> Pil Kim,<sup>16</sup> Yiling Yu,<sup>14</sup> Binghao Wu,<sup>14</sup> and Jun Zhu<sup>1</sup>

## KEY POINTS

- **Zanubrutinib demonstrated deep and durable responses and a favorable safety profile in R/R MCL at median 35.3 months follow-up.**
- **Zanubrutinib provided a high response rate (84% [78% CR]) and extended PFS (median 33.0 months) in patients with R/R MCL.**





## **Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma**


Verònica Fernández<sup>1</sup>, Olga Salamero<sup>2</sup>, Blanca Espinet<sup>3</sup>, Francesc Solé<sup>3</sup>, Cristina Royo<sup>1</sup>, Alba Navarro<sup>1</sup>, Francisca Camacho<sup>4</sup>, Silvia Beà<sup>1</sup>, Elena Hartmann<sup>5</sup>, Virginia Amador<sup>1</sup>, Luis Hernández<sup>1</sup>, Claudio Agostinelli<sup>6</sup>, Rachel L. Sargent<sup>7</sup>, Maria Rozman<sup>1</sup>, Marta Aymerich<sup>1</sup>, Dolors Colomer<sup>1</sup>, Neus Villamor<sup>1</sup>, Steven H. Swerdlow<sup>7</sup>, Stefano A. Pileri<sup>6</sup>, Francesc Bosch<sup>2</sup>, Miguel A. Piris<sup>4</sup>, Emili Montserrat<sup>2</sup>, German Ott<sup>8</sup>, Andreas Rosenwald<sup>5</sup>, Armando López-Guillermo<sup>2</sup>, Pedro Jares<sup>1</sup>, Sergi Serrano<sup>3</sup>, and Elías Campo<sup>1</sup>

## **Molecular Subsets of Mantle Cell Lymphoma Defined by the *IGHV* Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features**

Alba Navarro<sup>1</sup>, Guillem Clot<sup>1</sup>, Cristina Royo<sup>1</sup>, Pedro Jares<sup>1</sup>, Anastasia Hadzidimitriou<sup>4</sup>, Andreas Agathangelidis<sup>4,5</sup>, Vasilis Bikos<sup>4</sup>, Nikos Darzentas<sup>4</sup>, Theodora Papadaki<sup>7</sup>, Itziar Salaverria<sup>1,8</sup>, Magda Pinyol<sup>1</sup>, Xavier Puig<sup>2</sup>, Jara Palomero<sup>1</sup>, Maria Carmela Vegliante<sup>1</sup>, Virginia Amador<sup>1</sup>, Alejandra Martinez-Trillos<sup>1</sup>, Lenka Stefancikova<sup>12</sup>, Adrian Wiestner<sup>13</sup>, Wyndham Wilson<sup>13</sup>, Christiane Pott<sup>9</sup>, Maria Jose Calasanz<sup>3</sup>, Nicola Trim<sup>14</sup>, Wendy Erber<sup>15</sup>, Birgitta Sander<sup>16</sup>, German Ott<sup>10</sup>, Andreas Rosenwald<sup>11</sup>, Dolors Colomer<sup>1</sup>, Eva Giné<sup>1</sup>, Reiner Siebert<sup>8</sup>, Armando Lopez-Guillermo<sup>1</sup>, Kostas Stamatopoulos<sup>4,6</sup>, Silvia Beà<sup>1</sup>, and Elías Campo<sup>1</sup>




---









	<b>cMCL (n=15)</b>	<b>iMCL (n=12)</b>	<b>P value</b>
B symptoms (%)	33	0	0.03
Non-ambulatory performance status ECOG≥2 (%)	70	0	0.01
<b>Nodal presentation (lymph nodes &gt;1 cm) (%)*</b>	<b>93</b>	<b>17</b>	<b>&lt;0.001</b>
High serum LDH* (%)	46	0	0.03
Intermediate or high-risk MIPI	46	0	0.016
Morphology	13	67	0.007
Small cell (%)	74	33	
Classical	13	-	
Blastoid			
<b><i>IGHV</i> gene hypermutations (&gt;5%)</b>	<b>20</b>	<b>70</b>	<b>&lt; 0.04</b>
<b>Genomic Profile</b>			
<b>1.imbalance</b>	<b>13</b>	<b>100</b>	<b>&lt;0.001</b>
<b>≥ 2 imbalances</b>	<b>87</b>	<b>0</b>	
Chemotherapy at any time (%)	100	17	
<b>Dead patients (%)</b>	<b>47</b>	<b>0</b>	<b>&lt;0.001</b>
5-year overall survival (%)	49	100	0.03






**LN MCL shows a specific gene signature and SOX11 negativity**






Scaled Expression Value



- nnMCL
- Undetermined
- cMCL



Variable	Total	L-MCL16 prediction			P value (cMCL vs nnMCL)
		cMCL	nnMCL	Undetermined	
Number of cases (%)	70	39 (56)	26 (37)	5 (7)	
<b>Follow-up data</b>					
Median follow-up, mo	43	35	88	30	.019
Mean time from diagnosis to sample (range), mo	16.6 (0-185)	2.8 (0-36)	36 (0-185)	22.8 (0-92)	.002
Dead patients, n (%)	24/70 (34)	16/39 (41)	7/26 (27)	1/5 (20)	.296
Treated at 3 y from diagnosis, % (95% CI)	65 (51-75)	88 (70-96)	31 (9-48)	47 (0-79)	<.001
Treated at 3 y from sampling, % (95% CI)	71 (57-80)	89 (73-96)	44 (19-62)	47 (0-79)	<.001
3-y OS, diagnosis, % (95% CI)	78 (69-89)	69 (55-86)	92 (81-100)	80 (52-100)	.006
3-y OS, sampling, % (95% CI)	72 (61-85)	68 (53-86)	79 (62-100)	80 (52-100)	.379





# *In-situ* mantle cell lymphoma—a report of two cases

2008 Blackwell Publishing Ltd, *Histopathology*, 52, 239–262.


N Aqel  
F Barker  
K Patel  
K N Naresh


*Departments of Histopathology and Haematology,  
Northwick Park Hospital,  
Hillingdon Hospital & Hammersmith Hospital, London, UK*

## ***In situ* mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior**

by Alejandra Carvajal-Cuenca, Luz F. Sua, Nhora M. Silva, Stefania Pittaluga, Cristina Royo, Joo Y. Song, Rachel L. Sargent, Blanca Espinet, Fina Climent, Samuel A. Jacobs, Jan Delabie, Kikkeri N. Naresh, Adam Bagg, Pierre Brousset, Roger A. Warnke, Sergi Serrano, Nancy Lee Harris, Steven H. Swerdlow, Elaine S. Jaffe, and Elias Campo

*Haematologica* 2011 [Epub ahead of print]





LN with Cyclin D1+  
In Situ Pattern



SOX11 negative

May be CD5 negative  
Rare event: <1% of LNs  
Low risk of Progression (<10%)

SOX11 positive

More often CD5 positive  
Higher risk of progression  
Similar pattern can be seen  
at relapse or at distant sites



## **Letter to the Editor**

***Leukemia* 23, 1190-1193 (June 2009) | doi:10.1038/leu.2009.31**

**t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals.**

**Y Lecluse, P Lebailly, S Roulland, A-C Gac, B Nadel and P Gauduchon**

### **Abstract**

Several lymphoma- and leukaemia-associated chromosomal translocations are present in the peripheral blood of healthy individuals (HI). Translocation t(14;18), the genetic hallmark of follicular lymphoma (FL) that juxtaposes the BCL2 proto-oncogene near the immunoglobulin heavy chain (IGH) locus, can be detected in most HI at highly variable frequency.

ngiyabonga  
tesekkür ederim

рахмат  
danke 謝謝

tapadh leat

Баярлалаа  
спасибо

merci  
kia ora  
barka  
welalin  
tack  
dank je  
misaotra  
matondo  
paldies  
grazzi  
mahalo

gracias

faatetai lava  
nanni  
nandri  
kiitos  
dankie  
dhanyavad  
mauruuru  
koszonom  
hvala  
mauruuru

vinaka  
спасиби  
blagodaram  
akun  
dankon  
aciul

dziękuję

хвала  
asante  
manana  
obrigada  
murakoze  
tenki

enkosi  
bedankt

szukriya

chnorakaloutioun  
gratias  
ago  
gracies  
sulpay

sukriya

kop  
khun  
krap

taiku

go  
raibh  
maith  
agat

obrigado

sagolon

shukriya

kop  
khun  
krap

grazie

arigatō

takk

dakujem

trugarez

najis  
tuke

terima kasih

tanemirt  
rahmet

grazie

arigatō

takk

dakujem

merci

didid  
madioba

kam sah  
hamnida

xiexie

ευχαριστώ  
diolch  
dhanyavadagalu  
shukriya  
merce  
merci

তোমাকে ধন্যবাদ  
감사합니다